Insmed Halts CRSsNP Program After Phase 2b Failure

The latest announcement is out from Insmed ( (INSM) ).

On December 17, 2025, Insmed announced the Phase 2b BiRCh study of brensocatib for chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet primary or secondary efficacy endpoints, prompting the discontinuation of the CRSsNP program. The study, conducted at 104 global sites with 288 participants, showed no significant improvement in outcomes compared to the placebo, but brensocatib was well tolerated without new safety concerns. Additionally, Insmed acquired INS1148, a Phase 2-ready investigational monoclonal antibody targeting respiratory, immunological, and inflammatory diseases, marking a strategic move that could enhance its pipeline for high unmet medical needs.

The most recent analyst rating on (INSM) stock is a Buy with a $256.00 price target. To see the full list of analyst forecasts on Insmed stock, see the INSM Stock Forecast page.

Spark’s Take on INSM Stock

According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.

The overall stock score reflects Insmed’s strong technical indicators and positive corporate events, such as the approval of BRINSUPRI in the EU. However, significant challenges in financial performance, particularly in profitability and cash flow, weigh heavily on the score. The balanced outlook from the earnings call and concerns about valuation further moderate the overall assessment.

To see Spark’s full report on INSM stock, click here.

More about Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing therapies for serious diseases, particularly in pulmonary and inflammatory conditions. The company is headquartered in Bridgewater, New Jersey, and has advanced programs in drug discovery and multiple approved therapies targeting chronic lung diseases.

Average Trading Volume: 2,446,954

Technical Sentiment Signal: Buy

Current Market Cap: $42.8B

For a thorough assessment of INSM stock, go to TipRanks’ Stock Analysis page.